Executive Interview – Futura Medical

Executive Interview – Futura Medical

The next 12 months should mark the defining events in Futura Medical’s journey towards sustainable profitability. Futura Medical operates with a low fixed-cost base, seeking to outsource most major operations (such as conducting clinical trials, preparing regulatory submissions, formulation and stability testing) and using specialist contractors as appropriate. This ‘virtual’ approach is particularly suitable for a small development player, allowing spending to be tightly controlled with cash outflows occurring only when really needed. With a cash burn of around £2m pa, Futura Medical should be funded through to profitability. The recent £14m placing allows a material acceleration of new product development, notably the pain relief gel portfolio.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free